Alzheimer's disease: Pharmacological treatment and management

Rafael A. Rivas-Vazquez, Enrique J. Carrazana, Gustavo Rey, Mark A. Blais, David A. Racher

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The expected rise in prevalence rates of Alzheimer's disease over the next several decade has generated a great deal of attention at all levels of society, including governmental and scientific communities. These concerns have resulted in a vast number of research studies which have yielded medications focusing primarily on the symptomatic relief of the cognitive, neuropsychiatric and behavioral alterations felt to be pathognomic of the disease. Medical and pharmacological interventions which impact the onset or delay the progression of the illness are not yet readily available. We review and discuss the medications which are currently used for the symptomatic treatment and management of the disease, as well as discuss new pharmacological strategies which are under investigation and development.

Original languageEnglish (US)
Pages (from-to)93-109
Number of pages17
JournalClinical Neuropsychologist
Volume14
Issue number1
StatePublished - 2000

Fingerprint

Alzheimer Disease
Pharmacology
Disease Management
Therapeutics
Research
Medication
Alzheimer's Disease
Scientific Community
Progression
Alteration
Onset
Illness
Relief

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Rivas-Vazquez, R. A., Carrazana, E. J., Rey, G., Blais, M. A., & Racher, D. A. (2000). Alzheimer's disease: Pharmacological treatment and management. Clinical Neuropsychologist, 14(1), 93-109.

Alzheimer's disease : Pharmacological treatment and management. / Rivas-Vazquez, Rafael A.; Carrazana, Enrique J.; Rey, Gustavo; Blais, Mark A.; Racher, David A.

In: Clinical Neuropsychologist, Vol. 14, No. 1, 2000, p. 93-109.

Research output: Contribution to journalArticle

Rivas-Vazquez, RA, Carrazana, EJ, Rey, G, Blais, MA & Racher, DA 2000, 'Alzheimer's disease: Pharmacological treatment and management', Clinical Neuropsychologist, vol. 14, no. 1, pp. 93-109.
Rivas-Vazquez RA, Carrazana EJ, Rey G, Blais MA, Racher DA. Alzheimer's disease: Pharmacological treatment and management. Clinical Neuropsychologist. 2000;14(1):93-109.
Rivas-Vazquez, Rafael A. ; Carrazana, Enrique J. ; Rey, Gustavo ; Blais, Mark A. ; Racher, David A. / Alzheimer's disease : Pharmacological treatment and management. In: Clinical Neuropsychologist. 2000 ; Vol. 14, No. 1. pp. 93-109.
@article{a3ce47aee1c947c8957d39872b18b725,
title = "Alzheimer's disease: Pharmacological treatment and management",
abstract = "The expected rise in prevalence rates of Alzheimer's disease over the next several decade has generated a great deal of attention at all levels of society, including governmental and scientific communities. These concerns have resulted in a vast number of research studies which have yielded medications focusing primarily on the symptomatic relief of the cognitive, neuropsychiatric and behavioral alterations felt to be pathognomic of the disease. Medical and pharmacological interventions which impact the onset or delay the progression of the illness are not yet readily available. We review and discuss the medications which are currently used for the symptomatic treatment and management of the disease, as well as discuss new pharmacological strategies which are under investigation and development.",
author = "Rivas-Vazquez, {Rafael A.} and Carrazana, {Enrique J.} and Gustavo Rey and Blais, {Mark A.} and Racher, {David A.}",
year = "2000",
language = "English (US)",
volume = "14",
pages = "93--109",
journal = "Clinical Neuropsychologist",
issn = "1385-4046",
publisher = "Swets & Zeitlinger",
number = "1",

}

TY - JOUR

T1 - Alzheimer's disease

T2 - Pharmacological treatment and management

AU - Rivas-Vazquez, Rafael A.

AU - Carrazana, Enrique J.

AU - Rey, Gustavo

AU - Blais, Mark A.

AU - Racher, David A.

PY - 2000

Y1 - 2000

N2 - The expected rise in prevalence rates of Alzheimer's disease over the next several decade has generated a great deal of attention at all levels of society, including governmental and scientific communities. These concerns have resulted in a vast number of research studies which have yielded medications focusing primarily on the symptomatic relief of the cognitive, neuropsychiatric and behavioral alterations felt to be pathognomic of the disease. Medical and pharmacological interventions which impact the onset or delay the progression of the illness are not yet readily available. We review and discuss the medications which are currently used for the symptomatic treatment and management of the disease, as well as discuss new pharmacological strategies which are under investigation and development.

AB - The expected rise in prevalence rates of Alzheimer's disease over the next several decade has generated a great deal of attention at all levels of society, including governmental and scientific communities. These concerns have resulted in a vast number of research studies which have yielded medications focusing primarily on the symptomatic relief of the cognitive, neuropsychiatric and behavioral alterations felt to be pathognomic of the disease. Medical and pharmacological interventions which impact the onset or delay the progression of the illness are not yet readily available. We review and discuss the medications which are currently used for the symptomatic treatment and management of the disease, as well as discuss new pharmacological strategies which are under investigation and development.

UR - http://www.scopus.com/inward/record.url?scp=0033887141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033887141&partnerID=8YFLogxK

M3 - Article

C2 - 10855063

AN - SCOPUS:0033887141

VL - 14

SP - 93

EP - 109

JO - Clinical Neuropsychologist

JF - Clinical Neuropsychologist

SN - 1385-4046

IS - 1

ER -